XBLJ-13

N/A

Report date: 2022/01/05 15:24:33
NME

Base Information

Drug NameXBLJ-13
Drug Alias NameXBLJ-13
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDiscoidin domain receptor 1 antagonistsDiscoidin domain-containing receptor 2 inhibitors
TargetsDiscoidin domain receptor 1Discoidin domain-containing receptor 2
Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A